DiscoverMedical News PodcastIs FDA-backed elastography poised to replace biopsy as the driver of MASH drug development?
Is FDA-backed elastography poised to replace biopsy as the driver of MASH drug development?

Is FDA-backed elastography poised to replace biopsy as the driver of MASH drug development?

Update: 2025-09-11
Share

Description

The FDA has endorsed vibration-controlled transient elastography as a surrogate endpoint for MASH trials, marking the first non-invasive alternative to liver biopsy. A Japanese cohort study linked breakfast skipping and late dinners to higher fracture risk, with combined habits raising risk by nearly 25%. Finally, a global meta-analysis suggests shingles vaccination reduces major cardiovascular events by ~16–18%, though most evidence is observational.
Comments 
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Is FDA-backed elastography poised to replace biopsy as the driver of MASH drug development?

Is FDA-backed elastography poised to replace biopsy as the driver of MASH drug development?

PeerDirect Publishing